Introduction
Inactivation of the p53 tumor suppressor is to date the most common molecular alteration detected in human malignancies. Loss of p53 function can occur by p53 gene mutation or through direct interference by associating viral or cellular oncoproteins (Gottlieb and Oren, 1996) . When compared to cells with wildtype p53 (wt p53), p53 null cells are more resistant to the cytotoxic action of certain chemotherapeutic drugs both in vitro (Lowe et al., 1993) and in vivo (Lowe et al., 1994) . Moreover, patients possessing tumor cells harboring a p53 mutation typically have a poorer prognosis than those with wt p53 alleles (Velculescu and El-Deiry, 1996; Greenblatt et al., 1994) . These results suggest that p53 alteration analysis may be a useful prognostic determinant in the future. This type of analysis may be used to identify patients that have a reasonable chance of responding successfully to current treatment protocols. It could also be important in the identi®cation of experimental approaches that are more eective at destroying tumor cells with a defective p53 pathway. Clinical protocols aimed at treating patients based on the functional activity of p53 in tumor cells will need to rely on an assay that is (1) accurate, (2) able to screen a large number of samples in a short period of time, and (3) able to determine whether the p53 pathway, and not just the p53 gene, is functional. None of the current methods of p53 analysis (e.g. Single Strand Conformation Polymorphism (SSCP), immunohistochemistry or yeast based transcriptional assays measuring the transcriptional activity of p53) meet all of these criteria.
An assay capable of measuring the biochemical activity of p53 directly in primary human tumor cells may be one that is able to meet the requirements mentioned above. The best characterized biochemical function of p53 is its ability to act as a transcription factor. Wt p53, but not mutant forms, has been shown to bind DNA in a sequence speci®c manner and to upregulate the expression of genes possessing p53 response elements (Gottlieb and Oren, 1996; Levine, l997; Ko and Prives, 1996; Cox and Lane, 1995) . A number of genes (Bourdon et al., 1997) , including GADD45 (Kastan et al., 1992) , p21 (El-Deiry et al., 1993) , bax (Miyashita and Reed, 1995) , cyclin G (Okamoto and Beach, 1994) , IGF-BP3 (Bourdon et al., 1997; Buckbinder et al., 1995) and mdm2 (Wu et al., 1993) have been shown to possess p53 response elements and are transcriptionally up-regulated by wt p53. One might predict that tumors with wt p53 would have higher levels of these p53 regulated transcripts. Immunohistochemical analysis has shown a correlation between p53 gene status and the protein levels of certain p53 regulated genes in some tumors (Chilosi et al., 1996; Bukholm et al., 1997; Maestro et al., 1995) . However, the utility of this type of analysis may be hindered by the lack of accuracy, sensitivity and/or ability to quantitate. Moreover, because many of the p53 responsive genes have also been shown to be regulated by p53 independent mechanisms (de Vente et al., 1995; Parker et al., 1995; Li et al., 1996) , it remains unclear if the analysis of any downstream target of p53 will be a reliable indicator of p53 function.
As stated above, the human mdm2 gene is one of a number of genes that can be up-regulated by p53. The human mdm2 gene is regulated by two promoters, P1 and P2 (Zauberman et al., 1995) . mdm2-P1 regulates the level of transcripts initiating in exon 1 of the human mdm2 gene while the mdm2-P2 promoter possesses two p53 binding motifs and controls transcript initiation from exon 2. There are at least two good reasons why mdm2-P2 expression analysis should be evaluated as a determinant for p53 functional activity in human tumor cells. Firstly, unlike some other p53 responsive genes (deVente et al., 1995; Parker et al., 1995; Li et al., 1996) , the regulation of mdm2-P2 transcripts has been shown to be p53 dependent in vitro (Barak et al., 1993) and in vivo (Gottlieb et al., 1997) . In addition, since mdm2-P1 and mdm2-P2 transcripts possess dierent 5' untranslated sequences, RNase protection analysis can be used to quantitate the expression level of each of these sequences (Zauberman et al., 1995) . The aim of this study therefore was to determine whether there is a correlation between the level of mdm2-P2 transcripts and the status of the p53 gene in human leukemic cells.
Results
Regulation of mdm2-P2 transcripts in quiescent and growth stimulated p53 wt and p53 null cells Figure 1 depicts the genomic organization of the human mdm2 gene (Zauberman et al., 1995) and the mdm2 probe used for RNase protection studies. This exonl/ exon3 mdm2 probe was chosen for RNase protection studies because it can be used to measure mdm2-P1 and mdm2-P2 transcript levels simultaneously. To determine whether the expression pro®le of mdm2-P2 transcripts may be dierent in quiescent versus cycling cells, peripheral blood mononuclear cells (PBMCs) were analysed for the level of these transcripts before and after growth stimulation with PHA and Il-2. Figure 2a shows the levels of p53 and mdm2 protein, as well as total mdm2 RNA levels (as determined by Northern blot) and the level of mdm2-P1 and mdm2-P2 transcripts (as determined by RNase protection). Whilst the levels of total mdm2 RNA do not dramatically increase in growth stimulated cells, a signi®cant increase in p53 protein, mdm2-P2 transcripts and mdm2 protein levels is seen in growth stimulated PBMCs. These results are consistent with previous studies which have shown co-expression of p53 protein and mdm2 protein in PHA/Il-2 stimulated PBMCs (Martinez et al., 1995) and in human tumor cells (Maestro et al., 1995) , but not co-expression of p53 protein and mdm2 RNA in growth stimulated cells (Mosner and Deppert, 1994) . Human mdm2-P2 transcripts have been shown to be translated more eciently than human mdm2-P1 transcripts in vitro and in cells in culture (Landers et al., 1997) . Therefore, it is likely that the increase in mdm2 protein observed in growth stimulated cells is not due to a proportional increase in total mdm2 RNA, but is due to the induction of mdm2-P2 transcripts which possess an increased translational capacity.
These experiments showed an increase in both p53 protein and mdm2-P2 transcripts in growth stimulated cells. To determine whether an increase in mdm2-P2 levels may occur through p53 independent mechanisms, we measured the mdm2-P2 levels in PHA/Il-2 stimulated leukemic cells from two T-cell leukemia patients. One patient possessed tumor cells harboring wt p53 while the other possessed tumor cells that were p53 null. Figure 2b shows that the levels of mdm2-P2 transcripts in the PHA/Il-2 stimulated wt p53 leukemic cells were detectable whilst they are not detectable in the PHA/Il-2 stimulated p53 null leukemic cells. In contrast to mdm2-P2 levels, comparable levels of two other p53 responsive genes, p21/waf I/CIPl (El-Deiry et al., 1993) and bax (Miyashita and Reed, 1995) , were present in both the PHA/Il-2 stimulated wt p53 and p53 null leukemic cells (Figure 2b ). These results Figure 1 Regulation of human mdm2 gene expression (Zauberman et al., 1994) . Schematic representation of the mdm2 gene and the origin of transcripts arising from the P1 and P2 promoters of mdm2. p53-REs denote the two p53 binding motifs located in intron 1 of the mdm2 gene. The ®rst in frame AUG is noted for each set of transcripts, as well as the probe used in this study and the size of protected fragments generated by RNase protection analysis mdm2-P2 levels and p53 gene status in hematological malignancies EK Bull et al suggest that mdm2-P2 levels may be a more reliable indicator of p53 transactivation activity than at least these two p53 responsive genes in primary human leukemic cells.
Levels of mdm2-P1 and mdm2-P2 transcripts in p53 wt and p53 mutant lymphoid cell lines
We next measured the level of mdm2-P2 transcripts in a number of human cell lines with known p53 gene status. Figure 3 shows that there are no obvious dierences in the levels of mdm2-P1 transcripts in any of these lines. However, mdm2-P2 transcripts were only detected in those lines with wt p53 alleles. This analysis has been extended to at least ten more cell lines of various cell types and to date we have not found a line where the levels of mdm2-P2 transcripts do not correlate with p53 gene status (data not shown).
Analysis of mdm2-P1 and mdm2-P2 transcript levels in untreated primary leukemic cells
In order to determine whether or not mdm2-P2 transcript levels could be used to predict p53 transcriptional activity in primary leukemic cells, we ®rst determined mdm2-P2 levels and then the transactivation capacity of p53 that was cloned from cells isolated from patients with various hematological malignancies. We restricted this analysis to those patients who had an elevated white cell count (420610 9 cells per liter) and/or possessed blast cells that represented greater than 40% of the total white
Figure 2 (a) p53 and mdm2 expression pro®le in unstimulated and PHA/Il-2 stimulated PBMCs. PBMCs were isolated from a normal donor and were stimulated with PHA and Il-2. Western blot, Northern and RNase protection analysis was performed with material isolated from unstimulated (7) and stimulated cells (+) as described in the Materials and methods section. (b) Measurement of p53 protein and the levels of p53 regulated transcripts p21, bax and mdm2-P2 in PHA/IL-2 stimulated p53 null and p53 wt leukemic cells. PBMC's were isolated from two T-cell leukemic patients and were stimulated with PHA and Il-2. One patient (+/+) possessed wt p53 alleles disregard while the other (7/7) possessed a homozygous frame-shift mutation at codon 94 (Marks et al., 1996) . p53 protein levels were measured by a Western blot, bax and p21 by Northern blots, while mdm2-P1 and mdm2-P2 transcript levels were determined by RNase protection mdm2-P2 levels and p53 gene status in hematological malignancies EK Bull et al cell population. The use of samples from patients that ®t these criteria minimized the possibility that this study would be compromised by the presence of large numbers of non-malignant cells in the sample to be studied. Five patients (#'s 49, 51, 55, 59 and 68) possessed detectable levels of mdm2-P2 transcripts, while ®ve others (#'s 53, 70, 75, 76 and 78) did not ( Figure 4a ). The number of patients that possessed undetectable levels of mdm2-P2 transcripts was somewhat surprising considering that the incidence of p53 mutations has only been shown to be approximately 20% in various hematological malignancies (Imamura et al., 1994) . To determine whether these cells possessed a p53 gene capable of functioning as a transcriptional activator, we performed RT ± PCR with p53 primers spanning the p53 coding region on RNA isolated from each patient and then subcloned this product directly into a eukaryotic expression vector. Plasmid DNA was then prepared from a pool of at least 20 p53 insert containing clones and transfected into p53 null H1299 cells. Figure 4b shows that relatively equal levels of p53 RNA were produced in cells transfected with all expression construct pools. The data also shows that all patients with detectable levels of mdm2-P2 transcripts in their primary leukemic cells encoded p53 that was able to up-regulate mdm2-P2 levels in transfected cells. However, only two patients that possessed undetectable levels of mdm2-P2 levels turned out to encode a p53 protein that was de®cient at p53-mediated transactivation. SSCP analysis was also performed to determine the p53 gene status in the leukemic cells isolated from these patients. SSCP analysis identi®ed mutant conformers only in the leukemic cells from patients 53 and 75 (data not shown). These results suggest that mdm2-P2 levels can be used to predict wild ± type p53 alleles, but not a mutant p53 genotype in untreated primary leukemic cells.
Analysis of mdm2-P1 and mdm2-P2 transcript levels in cisplatin-treated primary leukemic cells
There are several possible explanations for why we were unable to detect mdm2-P2 transcripts in leukemic cells with apparent wt p53. One technical artifact that may explain these results is that our approach preferentially clones p53 from the wt p53 containing cells that make up a small percentage of the analysed population. We do not favor this explanation because our SSCP analysis did not identify a mixed population of PCR conformers. Considering that the level of p53 protein and mdm2-P2 transcripts could be regulated by the growth rate of cells (as is the case of growth stimulated PBMCs, see Figure 2a ), another possible explanation for these ®ndings is that the levels of transcriptionally active wt p53 protein are low in those leukemic cell populations with a low proliferative index. Alternatively, the p53 protein in the leukemic cells from these patients may be inactivated by mechanisms other than p53 gene mutation. Unfortunately, insucient patient samples were available to enable us to perform experiments that could begin to distinguish between these possibilities. Although increased levels of mdm2-P2 RNA were found to correlate with wt p53 in all cases involving untreated primary leukemic cells, the results presented above demonstrate that mdm2-P2 expression analysis is de®cient at determining p53 gene status in patients with undetectable levels of mdm2-P2 transcripts. mdm2-P2 RNA has been shown to be up-regulated in a p53 dependent manner during a DNA damage response both in vitro (Perry et al., 1993) and in vivo (Gottlieb et al., 1997) . Therefore, we next tested the possibility that the measurement of mdm2-P2 induction in primary leukemic cells treated with the DNA damaging agent cisplatin might be a better indicator of a functional or dysfunctional p53 protein. Leukemic cells from 14 additional cases were isolated and exposed to this drug. RNase protection was performed using RNA from both untreated and treated cells. p53 gene status for each patient was also determined by SSCP analysis and by measuring the ability of cloned p53 to up-regulate levels of mdm2-P2 and p21 transcripts in transfected H1299 cells. Table 1 shows that we were able to predict p53 gene status in 12/14 cases. Only two patients (66 and 74) were found to possess wt p53 containing cells where mdm2-P2 levels were induced less than twofold upon cisplatin exposure.
mdm2 and p53 protein levels in patients with wt p53 alleles and compromised mdm2-P2 induction by cisplatin It is possible that p53's transactivation function is compromised by mechanisms independent of p53 gene mutation in those two patients (66 and 74) harboring wt p53 alleles where no mdm2-P2 induction was observed upon cisplatin exposure. mdm2 overexpression has been shown to occur at a relatively high frequency in patients with leukemic cells containing wt p53 (Bueso-Ramos et al., 1993; Watanabe et al., 1994; Marks et al., 1997) . Therefore, we next measured mdm2 protein levels in leukemic cells from patients 66 and 74. Figure 5 clearly shows that the levels of mdm2 protein are elevated in cells from patient 74 when protein when compared to leukemic cells from other patients where mdm2-P2 transcripts were induced upon cisplatin exposure (patients 84 and 86). These results suggest that elevated levels of mdm2 protein in tumor cells isolated from patient 74 may account for the lack of mdm2-P2 induction by cisplatin in the leukemic cells from this patient. The mechanism by which p53 protein is unable to induce the expression of mdm2-P2 transcripts in the leukemic cells of patient 66 is unclear.
Discussion
The results presented here demonstrate that the level of mdm2-P2 transcripts can be used as an indicator of p53 gene status in cell lines and in primary leukemic cells. In cell lines, the measurement of the basal levels of mdm2-P2 RNA appears to be sucient for determining p53 gene status. In primary leukemic cells, the best correlation between p53 gene status and mdm2-P2 transcript levels was observed when the cells were treated with the chemotherapeutic drug cisplatin and mdm2-P2 inducibility was measured. Using these conditions, we were unable to predict p53 gene status in only two of fourteen cases. It would have been desirable to evaluate the inducibility of other p53 responsive genes in these two cases to verify that p53 transactivation function was de®cient in these tumor cells. Unfortunately, we did not have enough cells from either of these patients to perform these experiments. Nevertheless, one of these cases (#74) possessed levels of mdm2 protein that were clearly higher than all of the other patients analysed.
Furthermore, RNase protection analysis showed increased levels of mdm2-P1, but not mdm2-P2 transcripts in the leukemic cells obtained from this patient (data not shown Figure 4 (a) Measurement of mdm2-P1 and mdm2-P2 transcripts in 10 leukemic patient samples. PBMCs were isolated from leukemic patients possessing white cell counts greater than 20610 9 cells per liter and/or possessing blasts cells that were greater than 40% of the total white cells count. RNA was isolated with RNazol and RNase protection analysis was performed with 20 mg of total cellular RNA. The diagnosis of the patients are as follows: 49, AML; 51, AML; 53, AML; 55, AML; 59, AML; 68, AML; 70, CML; 75, CLL 76, AML; 78, AML. (b) Functional analysis of cloned p53 from 10 leukemic patients. p53 coding sequences were PCR ampli®ed from patient samples that were analysed for mdm2-P2 levels and subcloned into the pBK-CMV expression vector. Empty vector (V) and p53 expression constructs were then transfected into the H1299 line. RNA was prepared from transfected cells 24 h after transfection and analysed for p53, mdm2-P1 and mdm2-P2 levels as described in the Materials and methods section rule out the possibility that p53 inactivation is occurring through mechanisms independent of mdm2 overexpression, it is likely that the high levels of mdm2 protein are negatively aecting the transactivation capacity of p53 on the mdm2-P2 promoter in the leukemic cells from this individual.
Our results also show that the magnitude by which mdm2-P2 levels are induced by cisplatin treatment diers between individual patients; even those patients where no alteration in p53 or mdm2 expression can be detected (especially in the case of patient 66 where less than twofold induction of mdm2-P2 transcripts was measured). Whether this is due to a dierence in the way cisplatin is absorbed and/or metabolized by the leukemic cells, or more directly related to an alteration in the transactivation capacity of p53, is unclear. It is entirely possible that this lack of mdm2-P2 inducibility may not necessary re¯ect compromised p53 function in some tumors. p53 has been shown to induce apoptosis by mechanisms that are independent of p53-mediated transactivation (Caelles et al., 1994; Haupt et al., 1995) . In addition, p53 mutants have been identi®ed that retain some functional properties of p53, but are only able to regulate the expression of a subset of p53 responsive promoters (Ludwig et al., 1996) . It will therefore be important for future studies to determine if there is a correlation between mdm2-P2 induction and p53 functional activity in vivo.
The data presented here suggest that mdm2-P2 expression analysis can be used to determine the transcriptional activity of p53 in human tumor cells. The main appeal for using mdm2-P2 expression analysis to predict p53 function in tumor cells is due to its ability to detect when the p53 protein is rendered dysfunctional through mutation in the p53 gene, or when p53 is inactivated by mechanisms other than p53 gene mutation (e.g. mdm2 overexpression). Current methods such as p53 gene mutational analysis or yeast based assays measuring the transactivation function of cloned p53 will only identify the status of the p53 gene in patient samples; these methods cannot determine whether or not the pathway is functional in vivo. mdm2-P2 expression analysis could signi®cantly improve the ability to determine the status of the pathway in tumor samples, especially in cancers where p53 is inactivated by mechanisms that are independent of mutation (e.g. mdm2 overexpression in soft tissue sarcomas (Oliner et al., 1992) and in leukemia (Bueso-Ramos et al., 1993; Watanabe et al., 1994; Marks et al., 1997) . This assay can also be performed in a relatively short period of time and could be easily formulated to analyse large numbers of samples. Although our analysis was performed on a small number of patients, the reliability of detecting altered p53 appears good. A more reliable prediction rate will need to be determined in a study using a larger number of patients. Additional work will also need to be performed to determine if this assay can be used to determine p53 pathway status in other types of tumors, particulary in solid tumors where it may be dicult to obtain the number of cells needed for such a test, or where it may be problematic to obtain analysable RNA. An additional problem that may limit the utility of this system that is not encountered with SSCP or yeast based assays is its inability to detect a subpopulation of malignant cells with an altered p53 protein. It should be noted however that some of these problems may be eliminated by using other methods (e.g. RT ± PCR and/or in situ hybridization) aimed at detecting mdm2-P2 transcripts in cases where material Figure 5 mdm2 protein levels in PBMCs isolated from leukemic patients. Western blot analysis was performed as described in the Materials and methods section using the mdm2 speci®c antibody IF2. Ponceau S staining of the membrane demonstrated equal amounts of loaded protein (not shown) Abbreviations; NHL, Non-Hodgkins lymphoma; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; N, normal; wbc, white blood cell count 610 9 cells/liter); wt, wild-type; mut, mutant; r, sample obtained at relapse; SSCP, Single Stand Conformation Polymorphism. +++=4ten-fold induction, ++=5 ± 10-fold induction, +2 -4.9-fold induction, 7=5 two-fold induction is limiting or where there is a mixed population of cells present. Nevertheless, it is possible that mdm2-P2 expression analysis may be useful for identifying patients that have a reasonable chance of responding successfully to current treatment protocols. It could also be important in the identi®cation of experimental approaches that are more eective at destroying tumors cells with a defective p53 pathway (Bischo et al., 1996) .
Materials and methods

Patient samples
Leukemic patients analysed in this study all possessed a white cell count greater than 20610 9 cells per liter or possessed blast cells that comprised greater than 40% of the total white cells. All samples were collected prior to treatment. Mononuclear cells from venous blood was isolated by Ficoll-Hypaque (Pharmacia) density gradient sedimentation according to manufacturer's instructions. Cells were then washed once with phosphate-buered saline, pelleted and resuspended in freezing media (80% fetal bovine serum (Intergen)/10% RPMI 1640/10% dimethyl sulfoxide). Samples were stored in liquid nitrogen prior to analysis.
Cell lines and their p53 status
The Raji (B-cell), Hut78 (T-cell line), Jurkat (T-cell), Supt1 (T-cell line), and Molt4 (T-cell) cell lines possess mutant p53 alleles (Hainaut et al., 1997) while the AVM (B-cell) and VDS (B-cell) lines possess wt p53 alleles. All lines were maintained at 378C (5% CO 2 ) in RPMI 1640 containing antibiotics and 10% fetal bovine serum (FBS).
PBMC isolation and PHA/Il-2 stimulation
PBMCs were isolated from heparinized venous blood by centrifugation with Ficoll-Hypaque. Unstimulated PBMCs were placed directly in complete RPMI 1640 and used immediately for either RNA or protein analysis. To generate an actively proliferating short term culture of Tcells, isolated PBMCs were placed in complete RPMI 1640 media (10% fetal bovine serum/1% antibiotics) containing 1% PHA-M (Difco) for 3 days. Cells were then placed into culture media containing 3 units/ml Il-2 (Calbiochem) and were split 1 : 1 every other day with Il-2 containing media for 2 weeks. Cells were harvested for protein and RNA after 2 weeks of Il-2 exposure. This procedure was also used to expand T-cells from Sezary patients with known p53 gene status (Marks et al., 1996) .
Cisplatin treatment of cells
One610
7 cells at 5610 5 cells/ml were seeded into T25 asks and incubated overnight in complete RPMI 1640 media containing 10 mg/ml Cisplatin (Platinol, BristolMyers-Squib).
Western blot analysis
Frozen cell pellets were lysed in TENN buer (5 mM EDTA pH 8, 50 mM Tris pH 7.5, 0.5% Nonidet P-40, 150 mM NaCl) on ice for 10 min. After clari®cation by centrifugation, supernatant was transferred to a new tube and a small aliquot was set aside for protein determination by the Bradford method (BioRad). The protease inhibitors (®nal concentration in lysate noted) PMSF (1 mM), aprotinin (2 mg/ml), leupeptin (2 mg/ml), and soy trypsin inhibitor (1 mg/ml) were then added to the remaining cell lysate. A total of 100 mg of cellular protein was then mixed with equal amounts of 26SDS ± PAGE sample loading buer, boiled and separated on 7.5% SDS-polyacrylamide gels. Western blot analysis was then performed with 0.5 mg/ ml p53 DO-1 (AB-6, Calbiochem) or 3 mg/ml mdm2 IF2 (AB-1, Calbiochem).
Templates for probe synthesis
Oligos speci®c for exons 1 and 3 of mdm2 (5'-ATTAGTGCGTACGAGCGCCCAGT and 5'-AGTGT-CTTTTTGTGCACCAACAGAC) for bax (5'-GCTCT-GAGCAGATCATGAAGACAGG and 5'-CAGCCCATC-TTCTTCCAGATGGTGA) were used in RT ± PCR reactions to amplify speci®c sequences. PCR products corresponding to each cDNA fragment were then subcloned into pCRII (Invitrogen) and veri®ed by DNA sequencing. EcoRI liberated insert for bax was puri¯ed with glass milk (BIO101) and used as template in random priming probe synthesis reactions. To generate antisense probes for RNase protection, the mdm2 template was linearized with BamHI and a GAPDH template was linearlized with EcoRI prior to riboprobe synthesis.
RNA isolation and Northern blot analysis
Total cellular RNA was isolated with RNAzol B according to manufacturer's instructions. For Northern analyses, 10 mg of total cellular RNA was heat denatured, separated on 1% agarose-formaldehyde gels, transferred to Hybond-N + nylon membranes (Amersham) and probed with mdm2 and p21 as previously described (Marks et al., 1997) , or with a p53 probe obtained from PCR reactions derived from patient samples.
RNA probe synthesis and RNase protection analysis
Antisense mdm2 (1610 9 c.p.m.s./mg) and GAPDH (1610 9 c.p.m.s./mg) RNA probes were generated with T7 RNA polymerase using linearized template and puri®ed with Sephadex G-50. The GAPDH probe protects 100 bases of GAPDH RNA. The mdm2 probe gives rise to two dierent sizes of protected fragments. A 306 base protected product corresponds to transcripts of mdm2 that are regulated by the mdm2 P1 promoter while a 145 base protected fragment corresponds to transcripts of mdm2 that are regulated by the mdm2-P2 promoter containing the two p53 responsive elements (Zauberman et al., 1995) .
For RNase protection analysis, 20 mg of total cellular RNA was dried and resuspended in 28 ml hybridization buer (80% formamide, 40 mM PIPES pH 6.7, 0.4 M NaCl, 1 mM EDTA) containing 2610 6 c.p.m.s. of mdm2 and GAPDH RNA probes. This mixture was then heated to 858C for 5 min and incubated overnight at 458C. RNA hybrids were incubated at 378C for 1 h with 40 mg/ml RNase in 300 ml digestion buer (0.3 M NaCl, 10 mM Tris-HCL pH 7.4, 5 mM EDTA). RNase digestion was then stopped with 20 ml 10% SDS and 100 mg Proteinase K. RNA target: RNA probe hybrids were extracted once with phenol, once with chloroform and precipitated from ethanol with 40 mg carrier tRNA. Hybrids were resuspended in loading buer (80% formamide, 10 mM EDTA pH 8.0, 1 mg/ml xylene cyanol FF, 1 mg/ml bromophenol blue), placed at 958C for 5 min and run on sequencing gels. Gels were then dried and exposed to X-ray ®lm. Densitometry was performed with RFLP-scan software (Scanalytics), and the fold induction of mdm2-P2 transcripts was determined after standardization with the signal generated from the internal 100 bp GAPDH probe control.
p53 functional analysis
For cDNA synthesis, 2 mg of total RNA was incubated in a 10 ml reaction with 1 mg of oligo dT for 2 min at 908C in a 10 mM HEPES (pH 7.0), 1 mM EDTA (pH 8.0) buer and then cooled on ice. To this mixture was added 100 U of Moloney murine leukemia virus reverse transcriptase (Gibco-BRL), which was then incubated at 378C for 60 min in a ®nal volume of 20 ml according to the manufacturer's instructions. A 50 ml PCR reaction (total volume) was set up using 5 ml of the reverse transcriptase reaction, 800 mM deoxynucleoside triphosphates, 20 pmol of oligonucleotide 5'-GAGGAATTCTTTCCACGACGGT-GACACGCTT-3', 20 pmol of oligonucleotide 5'-GAGTC-TAGATCAGTCTGAGTCAGGCCCTTCTGT-3', 2.5 U Amplitaq DNA polymerase (Perkin-Elmer) and 0.75 U pfu polymerase (Stratagene) in 16PCR buer containing 1.5 mM MgCl 2 . Reactions were placed at 948C for 30 s, 648C for 30 s, 688C for 5 min for 40 cycles followed by a ®nal extension for 10 min. PCR products were restricted with EcoRI and XbaI, separated on agarose gels, glass extracted and cloned into the EcoRI/XbaI sites of pBK-CMV (Stratagene). At least 20 individual white colonies from each transformation reaction were pooled and grown overnight. Qiagen columns were then used to prepare plasmid DNA from these overnight cultures. To test for the transactivation activities of cloned p53 sequences, plasmid DNA was transfected into the p53 null H1299 cell line by the calcium phosphate method as described previously (Haines et al., 1994) . RNA was harvested from these transfectants 48 h after transfection and analysed for the levels of p21 and mdm2-P2 transcripts by Northern blot and RNase protection, respectively. p53 SSCP analysis PCR ampli®ed products used for cloning were also analysed for p53 mutations between codons 90 and 298 using two sets of primer combinations. Set 1 oligonucleotides (5'-CTGTCATCTTCTGTCCCTTCCCA-3' and 5'-TCTGTCATCCAAATACTCCACACG-3') span codons 90 to 209 and set 2 oligonucleotides (5'-CTGGCCCCTC-CTCAGCATCTTAT-3' and 5'-CTCGTGGTGAGGCTC-CCCTTTCTT-3') cover amino acids 188 to 298 of p53. A 50 ml PCR reaction (total volume) was set up using a 1 : 100 dilution of ampli®ed product, 800 mM deoxynucleoside triphosphates, 20 pmol of each oligonucleotide, 2.5 U Amplitaq DNA polymerase in 16PCR buer containing 1.5 mM MgCl 2 . Reactions were placed at 948C for 30 s, 658C for 30 s, 728C for 5 min for 30 cycles followed by a ®nal extension for 10 min. A fraction of this product was then digested with HAEIII and both cut and uncut PCR products were loaded onto 6% polyacrylamide/5% glycerol gels. Samples were run at room temperature behind a cooling fan at 25 W for 6 h in 0.56TBE buer. Gels were then dried and subjected to autoradiography.
